Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT06295731
Title INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS>/=20 HNSCC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Inhibrx, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.